About Us

Corporate Development

We have established and will continue to selectively establish collaborations with pharmaceutical and diagnostic companies and leading academic institutions to enhance our research, development and commercialization capabilities.

Geron is developing, first-in-class cancer therapeutics. Imetelstat, Geron's lead telomerase inhibitor, is currently being evaluated in four Phase 2 clinical oncology studies for the following indications: non-small cell lung cancer, metastatic breast cancer, essential thrombocythemia and multiple myeloma. GRN1005, an LRP-directed peptide-drug conjugate, is being evaluated in two Phase 2 clinical trials, one for brain metastases arising from non-small cell lung cancer and the other for brain metastases arising from breast cancer.

We are actively looking for partners interested in acquiring or licensing the rights to our human embryonic stem cell programs, which include oligodendrocyte progenitor cells (GRNOPC1) for central nervous system disorders, cardiomyocytes (GRNCM1) for heart disease, pancreatic islet cells (GRNIC1) for diabetes, dendritic cells (GRNVAC2) as an immunotherapy vehicle and chondrocytes (GRNCHND1) for cartilage repair.

For more information about licensing or partnering opportunities please contact us at CorpDev@geron.com.

We are also interested in evaluating clinical and preclinical product candidates and enabling technologies that fit within our oncology therapeutic focus and complement our corporate and product development strategy.

To submit an opportunity that may meet our in-licensing interests and priorities, please provide a non-confidential overview for our consideration at CorpDev@geron.com.